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The evolutionarily novel genes originated through different molecular mechanisms are expressed in tumors.
Sometimes the expression of evolutionarily novel genes in tumors is highly specific. Moreover positive selection of
many human tumor-related genes in primate lineage suggests their involvement in the origin of new functions
beneficial to organisms.
It is suggested to consider the expression of evolutionarily young or novel genes in tumors as a new biological
phenomenon, a phenomenon of TSEEN (tumor specifically expressed, evolutionarily novel) genes.
Background
Evolutionarily novel genes are those novel genes which
originate in the germ cells of multicellular organisms
and thus can participate in evolution. Genes that origin-
ate in somatic cells (e.g. in tumor cells) and cannot be
passed to the progeny organisms are not considered as
evolutionarily novel.
Novel genes can originate from pre-existing genes or
de novo. The theory of the origin of novel genes is well
developed and the mechanisms of the origin of evolu-
tionarily novel genes are well understood and described
[8, 45, 58, 70, 76, 77, 110, 131, 132, 189, 194, 217]. But
there is a question in which cells of the evolving multi-
cellular organisms genes determining the evolutionary
innovations and morphological novelties are expressed.
There is a general correlation between the increase in
the gene number in the genomes of evolving organisms,
from one side, and the increase in the number of cell
types, the origin of other innovations and the overall
complexity, on the other [34, 91, 215]. The question is
how such adequate correlation was realized at the multi-
cellular level. An adequate increase in cell number that
accompanied the process of the origin of novel genes is
hard to imagine. More likely, some autonomous cellular
proliferative processes were recruited to provide the
space for the expression of new genes.
In my previous publications [88–90] and in my recently
published book “Evolution by Tumor Neofunctionaliza-
tion” [91] I suggested that heritable tumors – benign tu-
mors or tumors at the early stages of progression – may
provide extra cell masses for expression of evolutionary
novel genes and for emergence of evolutionary innova-
tions and morphological novelties. The non-trivial predic-
tion of this hypothesis is that we may find the expression
of evolutionarily novel genes in tumors.
Experiments in this direction performed in my lab
since early 2000s have indeed demonstrated the specific
or predominant expression of many evolutionarily young
or novel genes in tumors. These data will be discussed
in the first part of this review.
I also found in the literature descriptions of many
genes with similar dual specificity – tumor specifically
expressed, evolutionary novel. Such genes with dual
specificity were not purposefully searched for by the
authors and the connection of tumors and evolution
was not emphasized. Rather, the data on evolutionary
novelty and specificity of expression of certain genes
were the result of descriptive experiments and often
can be found among other described features of the
studied genes. Similar information may be found in
the results of genome-wide studies. Tumor specificity
of expression of genes originated by gene duplication,
from retrotransposons and endogenous retroviruses,
by exon shuffling or de novo will be discussed in the
second part of this review.
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The purposeful experimental search for evolutionarily
novel genes with tumor-specific expression
To study experimentally the prediction concerning
the expression of evolutionarily young or novel genes
in tumors we used two complementary approaches.
One was to study the evolutionary novelty of genes/
sequences with proven tumor specificity of expres-
sion. The other was to study tumor specificity of ex-
pression of genes/sequences with proven evolutionary
novelty. Both approaches found out genes/sequences
with dual specificity, i.e. tumor-specifically or tumor-
predominantly expressed and evolutionarily young or
novel.
The evolutionary novelty of tumor-specifically expressed
sequences
To find the sequences which are expressed in tumors but
not in normal tissues the global comparison of cDNA se-
quences from all available tumor-derived libraries with
cDNA sequences from all available normal tissue-derived
libraries was performed. The normal EST set was sub-
tracted in silico from the tumorous EST set [11].
The results showed that, in accordance with my pre-
diction, tumors indeed express hundreds of sequences
that are not expressed in normal tissues. About half of
discovered tumor-specific sequences lack long reading
frames (i.e., may be referred to non-coding RNAs) and
defined function [11, 51]. Among non-coding RNAs, the
long non-coding RNA [94] and candidate microRNA
(see ELFN1-AS1, a novel primate gene expressed pre-
dominantly in tumors) have been described.
The analysis of the relative evolutionary novelty of se-
quences retrieved from the paper [51] was performed.
The protein-coding sequences were studied by Protein-
Historian tool [28]. The nucleotide BLAST algorithm
and the original Python script [3] were used to analyze
the novelty of noncoding sequences. The orthologs of
tumor-specifically expressed sequences described by Bar-
anova and co-authors were searched in 26 completely
sequenced eukaryotic and prokaryotic genomes. The
curves of phylogenetic distribution of orthologs of these
sequences have been generated. The data suggest that
both sets of tumor-specifically expressed sequences are
relatively evolutionary novel. The non-coding tumor-
specifically expressed sequences are younger than
protein-coding tumor-specifically expressed sequences.
During last 39 million years of evolution, these se-
quences represented the youngest gene class in human
ancestors’ genomes [115, 116].
In vitro experiments intended to confirm that the se-
quences found in silico are indeed specifically expressed
in tumors were also carried out. cDNA panels from nor-
mal and tumor tissues were used for PCR with specific
primers. In total, 56 sequences described in [11] have
been studied in this way. Among them, nine were
confirmed to be highly tumor-specific [94, 95, 138].
The sequences that have been confirmed to be
tumor-specific are expressed in a vast variety of tu-
mors. For example, the sequence Hs. 202247 is
expressed in 46 tumor samples out of 56 examined
and in none of 27 normal tissues. One of the protein
products of the sequences that proved to be tumor-
specific appeared to be a promising immunogen for
antitumor vaccine development [138, 170]. However,
most of experimentally confirmed tumor-specific se-
quences appear to be non-coding RNAs.
The nine experimentally confirmed tumor-specific se-
quences were studied for their evolutionary novelty
using molecular-biological techniques, comparative gen-
omics analysis, the search for orthologous sequences
and sequence conservation analysis [92, 163, 164]. Eight
of the nine tumor-specifically expressed sequences are
either evolutionarily new (primates or humans) or rela-
tively young (mammals) (Table 1) and evolve neutrally
[92, 93, 162–164]. I suggest to call such sequences
Tumor-Specifically Expressed, Evolutionarily New Se-
quences, or TSEEN sequences.
The sequence Hs.285026 (HHLA1) contains ORF,
although the corresponding protein is not shown experi-
mentally. This sequence is similar to human de novo
protein-coding genes [86]. As far as corresponding pro-
tein has not been shown, this sequence may represent
the earlier stage of the novel gene origin comparing to
those described by D.G. Knowles and A. McLysaght.
This and other sequences described in our studies
(besides protein-coding sequences with established
functions) may represent proto-genes (gene precursors
which have not yet acquired functions and evolve
neutrally [29]) at different stages of their evolution to-
wards novel genes with protein or RNA related functions.
The sequence Hs.633957 represents this transition.
ELFN1-AS1, a novel primate gene expressed predominantly
in tumors
The human transcribed locus resides in the 7th chromo-
some and corresponds to the UniGene EST cluster
Hs.633957. It was found by our group to be expressed in
a tumor-specific manner by in silico analysis [11]. Later
these data were supported experimentally: specific tran-
scripts of the locus were detected in tumors of various
histological origins, but not in most of the healthy tis-
sues [94, 149, 150].
Experimental and in silico evidence that locus is a
stand-alone gene which has its own promoter and cap-
ability for alternative splicing was obtained. However,
only one splicing isoform is predominant. The gene was
assigned a gene symbol ELFN1-AS1, ELFN1 antisense
RNA 1 (non-protein coding), gene name approved by
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Table 1 Evolutionarily novel and young genes with tumor specific or predominant expression studied at the Biomedical Center
Single genes obtained by in silico subtraction studied for evolutionary novelty
Gene Protein/RNA Expression in tumors Expression in normal tissues Evolutionary novelty a References
Orthopedia homeobox (OTP) Hs.202247 RNA Lung, colon, ovary, stomach, breast,
kidney, bladder, uterus, lymphomas,
testis, small intestine, esophagus
No Mammalia [11, 91–95, 162–164]
Embryonic stem cell related (non-protein
coding) (ESRG) (Hs.720658)
RNA Ovary, testis, lung, lymphomas PBL, testis, thymus Humans [11, 91–95, 162–164]
Transcribed locus chr.8 (q24.21) (Hs.666899) RNA Lung, colon, prostate, kidney, bladder,
uterus, breast, testis, lymphomas,
ovary, stomach
Lymph node, spleen (very weak),
thymus (very weak)
Mammalia [11, 91–95, 162–164]
Transcribed locus chr.7 (q21.13) (Hs.150166) RNA Esophagus, stomach, small intestine,
kidney, bladder, uterus, ovary, breast,
lung, testis, lymphomas
Heart (very weak), kidney
(very weak), lung (very weak)
Mammalia [11, 91–95, 162–164]
ELFN1 antisense RNA 1 (non-protein coding)
(Hs.633957)
RNA Lung, colon, prostate, ovary, breast,
uterus, testis, lymphomas, esophagus,
stomach, small intestine
Liver, heart (very weak), stomach
(very weak)
Primates [11, 91–95, 149–152, 162–164]
Intergenic spacer region within rRNA
repeating unit (Hs.426704)
RNA Breast, pancreas, esophagus, liver,
small intestine, testis, lung
No Primates [11, 91–95, 162–164]
HERV-H LTR-associating 1 (HHLA1) (Hs.285026) Protein ? Esophagus, stomach, small intestine,
bladder, uterus, breast, testis
Bone marrow (very weak) Humans [11, 91–95, 162–164]
Small Proline-Rich Protein 1A (SPRR1A) (Hs.46320) Protein Lung, esophagus, colon, bladder, testis Thymus (very weak) Mammalia [11, 91–95, 162–164]
Evolutionarily novel single genes studied for tumor specificity of expression
Gene Protein/RNA Evolutionary novelty Expression in tumors Expression in normal
tissues
References
Chronic lymphocytic leukemia up-regulated1
(CLLU1) (Hs.730377)
Protein Humans Lung, stomach, prostate, spleen No [97]







Prostate and breast cancer overexpressed 1
(PBOV1) (Hs.302016)
Protein Humans Brain, lung, liver, gallbladder,
stomach, small intestine, colon,
breast, uterus, ovary, cervix,
ureter, bladder, prostate, testis,
adrenal, parotid, thymus, spleen,
lymphomas
No [96, 165]
Tumor- related gene classes studied for evolutionary novelty
Class of genes Number of genes Evolutionary novelty References
CT –antigen genes 276 36.7 % of human CT-genes originated
in Catarrhini, Hominidae and humans
[44]












Table 1 Evolutionarily novel and young genes with tumor specific or predominant expression studied at the Biomedical Center (Continued)
CT-X-antigen genes 60 31.4 % of CT-X genes are exclusive
to humans
[44]
39.1 % have ortologs in Catarrhini
and Homininae
BMC globally subtracted, tumor-specifically expressed
non-coding sequences
110 30 % originated after Catarrhini [51, 115, 116]
16 % originated after Homininae
BMC globally subtracted, tumor-specifically expressed
protein-coding sequences
73 More than 30 % originated after
Eutheria
[51, 115, 116]












Human Gene Nomenclature Committee. Our data point
to the miRNA function of ELFN1-AS1 with DPYS
mRNA being its primary target [151, 152].
This gene originated de novo from an intronic region
of a conservative gene ELFN1 (NCBI Ref. Seq.
NM_001128636.2) in primate lineage. Homologous se-
quences of this gene were identified by us in all pri-
mates, but the DNA sequence from the representative of
suborder Strepsirrhini Otolemur garnettii has more than
50 % differences from its human counterpart and forms
an outgroup on the phylogenetic tree. Thus ELFN1-AS1
could become transcriptionally active after divergence of
Strepsirrhini and Haplorhini primates. It is noteworthy
that all the Haplorhini primates have a region with 5 or
more E-boxes downstream of the DS site. This suggests
that ELFN1-AS1 gene since its origin could be c-Myc-
responsive.
Taken together, the data indicate that human tran-
scribed locus contains a gene for some non-coding
RNA, likely a microRNA. This gene combines features
of predominant expression in tumors and evolutionary
novelty [151, 152].
PBOV1, de novo originated human gene with tumor-specific
expression
In the study of PBOV1 gene the other approach was
used, i.e. the evolutionary novelty of the gene was stud-
ied first.
PBOV1 (UROC28, UC28) is a human protein-coding
gene with a 2501 bp single-exon mRNA and 135aa ORF.
The gene has been originally characterized by An and
co-workers [4]. This gene was mentioned among 12 hu-
man genes without orthologs in the mouse and dog
genomes in the paper of Clamp and co-authors [38]. We
studied the evolutionary novelty of this gene more care-
fully and found that the coding sequence of PBOV1 is
poorly conserved in the mammalian evolution and origi-
nated de novo in primate evolution through a series of
frame-shift and stop codon mutations. Consequently,
80 % of protein sequence is unique to humans. The
Ka/Ks ratio both in pairwise alignments and in mul-
tiple alignment of all primate sequences syntenic to
human coding sequence didn’t show any significant
differences from 1.0, indicating that the amino acid
sequence evolved neutrally. PBOV1 protein lacks any
annotated or predicted domains and over 60 % of its
sequence is predicted to be disordered. These findings
strongly suggest that human PBOV1 is a protein of a
very recent de novo evolutionary origin [165].
After establishing the evolutionary novelty of PBOV1
gene, the specificity of its expression in tumors and nor-
mal tissues was studied. PBOV1 has been previously re-
ported to be overexpressed in prostate, breast, and
bladder cancers [4]. We studied the expression of
PBOV1 using PCR on panels of cDNA from various nor-
mal and tumor tissues. The gene had a highly tumor-
specific expression profile. It was expressed in 20 out of
34 tumors of various origins but was not expressed in
any of the normal adult or fetal human tissues that we
tested (Figs. 1 and 2). The interesting feature of this re-
sult is that tumor specificity of PBOV1 expression was
predicted by us from its evolutionary novelty [96, 165].
Unlike cancer/testis antigens genes PBOV1 is
expressed from a GC-poor TATA-containing promoter
which is not influenced by DNA methylation and is not
active in testis. PBOV1 activation in tumors may depend
Fig. 1 PBOV1 expression measured by PCR in cDNA panels from human tumors. a Tumor cDNA Panel (BioChain Institute, USA): 1 – Brain
medulloblastoma, with glioma, 2 – Lung squamous cell carcinoma, 3 – Kidney granular cell carcinoma, 4 – Kidney clear cell carcinoma, 5 – Liver
cholangiocellular carcinoma, 6 – Hepatocellular carcinoma, 7 – Gallbladder adenocarcinoma, 8 – Esophagus squamous cell carcinoma, 9 – Stomach
signet ring cell carcinoma, 10 – Small Intestine adenocarcinoma, 11 – Colon papillary adenocarcinoma, 12 – Rectum adenocarcinoma, 13 – Breast
fibroadenoma, 14 – Ovary serous cystoadenocarcinoma, 15 – Fallopian tube medullary carcinoma, 16 – Uterus adenocarcinoma, 17 – Ureter papillary
transitional cell carcinoma, 18 – Bladder transitional cell carcinoma, 19 – Testis seminoma, 20 – Prostate adenocarcinoma, 21 – Malignant melanoma,
22 – Skeletal Muscle malignancy fibrous histocytoma, 23 – Adrenal pheochromocytoma, 24 – Non-Hodgkin’s lymphoma, 25 – Thyroid
papillary adenocarcinoma, 26 – Parotid mixed tumor, 27 – Pancreas adenocarcinoma, 28 – Thymus seminoma, 29 – Spleen serous adenocarcinoma,
30 – Hodgkin’s lymphoma, 31 – T cell Hodgkin’s lymphoma, 32 – Malignant lymphoma. NC – PCR with no template, PC – PCR with human DNA. b
PBOV1 expression in clinical tumor samples. PBOV1 is expressed in breast cancer (9–250), ovary cancer (1, 6), cervical cancer (2, 13), endometrial cancer
(156, 270), lung cancer (12, 14, 17), seminoma (7), meningioma (63), non-Hodgkin lymphomas (67, 82, 92, 102, 113). From open access paper [165].
Copyright of authors
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on sex hormone receptors, C/EBP transcription factors
and Hedgehog signaling pathway. Although the PBOV1
protein has recently originated de novo and thus has no
identifiable structural or functional signatures, a mis-
sense SNP (single nucleotide polymorphism) in it has
been previously associated with an increased risk of
breast cancer. Using publicly available data we found
that higher level of PBOV1 expression in breast cancer
and glioma samples were significantly associated with a
positive disease outcome. PBOV1 is also highly expressed
in primary but not recurrent high-grade gliomas, suggest-
ing that immunoediting against PBOV1-expressing cancer
cells might occur over the course of disease. We propose
that PBOV1 is a novel tumor suppressor gene which
might act by provoking the cytotoxic immune response
against cancer cells that express it. We speculate that this
property might be a source of phenotypic feedback that fa-
cilitated PBOV1 gene fixation in human evolution [165].
The evolutionary novelty of human cancer/testis antigen
genes
Cancer/testis antigen genes (CTA or CT genes) code
for a subgroup of tumor antigens expressed predom-
inantly in testis and different tumors. CT antigens
may be also expressed in placenta, in female germ
cells, and in the brain [33, 64, 175, 209, 210] (see dis-
cussion of CT genes expression in the brain in [91]).
At the time of the study, CTDatabase (http://
www.cta.lncc.br) included 265 CT genes and 149 CT
gene families.
The hypothesis of the expression of evolutionarily
novel genes in tumors explains this otherwise strange
cancer-testis association paradox: as far as the origin of
evolutionarily novel genes is connected with their ex-
pression in germ cells, cancer/testis genes are novel
genes which are expressed in tumors.
So I suggested that cancer/testis antigen genes
should be evolutionarily new or young genes. In order
to prove this prediction, the presence of genes ortho-
logous to human cancer-testis genes in human lineage
was studied [44]. This analysis was performed separ-
ately for genes located on the X chromosome and
autosomal cancer/testis genes, as far as extensive traf-
fic of novel genes has been described for mammalian
X chromosome [16, 46, 103].
Orthologs of each of CT genes were searched
among annotated genes in several completely se-
quenced eukaryotic genomes using HomoloGene tool
of NCBI [168] and distributions of orthologs of all
CT-X genes, all autosomal CT genes, all human CT
genes and all annotated protein coding genes from
human genome in 11 taxa of human evolutionary
lineage were built. It was shown that 31.4 % of CT-X
genes are exclusive for humans and 39.1 % of CT-X
genes have orthologs originated in Catarrhini and
Fig. 2 Expression of PBOV1 and GAPDH (positive control) measured by PCR in cDNA panels from human normal tissues. a Human MTC Panel I
(1–8), Human MTC Panel II (9–16): 1 – brain, 2 ¬– heart, 3 – kidney, 4 – liver, 5 – lung, 6 – pancreas, 7 – placenta, 8 – skeletal muscle, 9 – colon,
10 – ovary, 11 – peripheral blood leukocyte, 12 – prostate, 13 – small intestine, 14 – spleen, 15 – testis, 16 – thymus. b Human Digestive System
MTC Panel: 1 – cecum, 2 – colon, ascending 3 – colon, descending 4 – colon, transverse 5 – duodenum, 6 – esophagus, 7 – ileocecum, 8 –
ileum, 9 – jejunum, 10 – liver, 11 – rectum, 12 – stomach. c Human Immune System MTC Panel (1–7), Human Fetal MTC Panel(8–15): 1 – bone
marrow, 2 – fetal liver, 3 – lymph node, 4 – peripheral blood leukocyte, 5 – spleen, 6 – thymus, 7 – tonsil, 8 – fetal brain, 9 – fetal heart, 10 – fetal
kidney, 11 – fetal liver, 12 – fetal lung, 13 – fetal skeletal muscle, 14 – fetal spleen, 15 – fetal thymus; A-C: NC – PCR with no template, PC – PCR
with human DNA. From open access paper [165]. Copyright of authors
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Homininae. Thereby the majority of human CT-X
genes (70.5 %) are novel or young for humans.
Altogether 36.7 % of all human CT genes originated in
Catarrhini, Homininae and humans. It was also found
that 30 % of all human CT genes originated in Eutheria.
These CT genes acquired functions in Eutheria. This in-
dicates the importance of processes in which tumors
and CT antigens were involved during the evolution of
Eutheria. CT genes originated in Eutheria are located
mainly on autosomes. CT genes originated in Catarrhini,
Homininae and humans are located predominantly on X
chromosome. This difference is probably related to
important events in evolution of mammalian X
chromosome since the origin of Eutheria [99], espe-
cially to the acquisition of a special role in the origin
of novel genes [77].
Thus the majority of CT-X genes are either novel or
young for humans, and majority of all human CT genes
(>70 %) originated during or after the origin of Eutheria.
These results suggest that the whole class of human CT
genes is relatively evolutionarily new [44].
Our data are in good correspondence with evidence
obtained by other groups on particular families of CT
genes. I found the evidence in the literature that at least
7 families (of 149 families know by that time) of CT
genes (MAGE-1, PRAME, SPANX-A/D, GAGE, XAGE,
CT45 and CT47) and many CT genes located on the X
chromosome (CT-X genes) were either new or young
(reviewed in [91]. Later it was found that one more CT
gene family, CTAGE (cutaneous T-cell-lymphoma-asso-
ciated antigen) shows a rapid and primate specific ex-
pansion, especially in humans, which starts with an
ancestral retroposition in the Haplorhini ancestor
followed by DNA-based duplications [214]. But our
study [44] was the first systematic study of the evolu-
tionary novelty of the whole class of CT genes which
showed that it is relatively evolutionarily novel. Thus
our prediction of the evolutionary novelty of the whole
class of CT genes turned out to be correct.
The relative evolutionary novelty of the whole class of
CT genes confirms the prediction about expression of
evolutionarily young and novel genes in tumors. The ex-
pression of cancer/testis genes in tumors thus appears as
a natural phenomenon, not an aberrant process as inter-
preted by most of authors (e.g. [1, 27, 32, 36, 175, 214]).
More discussion of evolutionary novelty of CT genes
may be found in my recent book [91].
The list of single genes and gene classes studied by our
group at the Biomedical Center is presented in Table 1.
The data obtained by our group, both on individual
genes and on large groups of genes, suggest that tumor
specifically expressed, evolutionarily novel (TSEEN)
genes could represent a new biological phenomenon, a
phenomenon of TSEEN genes [91]. That is why I looked
in the literature for the evidence about similar kind of
genes, i.e. evolutionarily novel, tumor specifically expressed.
Analysis of the literature data related to TSEEN genes
It turned out that many examples of genes with dual
specificity –evolutionarily novel, tumor specifically
expressed – could be found in the literature but serious
attention was never paid to this association. Below I will
discuss the tumor specificity of expression of genes orig-
inated by different mechanisms - by gene duplication,
from retrotransposons and endogenous retroviruses, by
exon shuffling or de novo. As far as positive Darwinian
selection is a feature of many evolutionarily novel genes,
human tumor-related genes positively selected in pri-
mate lineage will be also discussed.
Expression of pseudogenes in tumors
Gene duplication is a major way of genome evolution.
The original hypothesis [131] suggested that pre-existing
genes are under control of natural selection, and their
evolution is constrained within their existing function.
The extra copy of existing gene gets out of control of
the natural selection, so that accumulation of mutations
in this extra copy may lead to the origin of a novel gene
with related or even new function. Gene duplication is
considered as providing the “row material” for the origin
of new genes. This concept also suggests that the major-
ity of duplicates becomes inactive pseudogenes due to
degenerative mutations, and only rarely beneficial muta-
tions would lead to the emergence of a new gene with a
novel function [131]. But the term “pseudogene” was
first introduced by C. Jacq and co-authors in 1977 [72].
The DNA-mediated mechanisms of gene duplication
include unequal crossing over, tandem, segmental,
chromosomal or genome duplications. The resulting
gene duplicates may be organized in tandem, inter-
spersed or polyploid manner. Segmental duplications are
large interspersed segments of DNA with high sequence
identity (>90 %), usually separated by >1Mb of unique
sequences [120].
RNA-based gene duplication, or retroposition, creates
duplicate genes by reverse transcription of RNAs from
parental genes. RNAs from all categories generate retro-
sequences that may be exapted as novel genes or regula-
tory elements [21]. Retrogenes are most abundant in
mammals where long interspersed nuclear elements
(LINEs) that provide the enzyme reverse transcriptase
for retroposition are widespread. The majority of retro-
genes is produced by genes with high levels of germline
expression. They often originate from the X chromo-
some [16, 76]. A new retrogene is intronless, contains a
poly(A) tract, and may be flanked by short duplicate se-
quences [15, 104].
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DNA-mediated gene duplication is more frequent
event in genome evolution, while RNA-based gene du-
plication is more capable to generate genes with novel
functions. The retroposition is less likely to provide
expressed daughter retrocopies than segmental DNA du-
plication because retrocopies do not contain regulatory
elements. So, new promoters and enhancers should
somehow be recruited for the origin of new genes, and
several mechanisms of such recruitment are described
[76, 77]. Retrogenes usually locate on chromosomes dif-
ferent from that of parental genes. Mammalian X
chromosome demonstrates extensive retrogene traffic
[46]. For reasons of different location and new promoter
recruitment, the transcribed retrogenes are more capable
to evolve new expression patterns and novel functional
roles than gene duplicates arising by DNA segmental
duplication [76, 77]. Retrogenes, like duplicates origi-
nated through DNA-mediated mechanisms, might pro-
vide the raw material for the origin of evolutionarily
novel genes and functionally important evolutionary in-
novations [76, 119, 197]. At least one functional retro-
gene per million years originated in primate lineage that
led to humans [119].
In accordance with two major ways of gene duplica-
tion – DNA-based and RNA-based mechanisms – two
types of pseudogenes are categorized as duplicated and
processed pseudogenes, accordingly [105, 148]. One
more group of pseudogenes includes so called “unitary”
pseudogenes that arise through spontaneous mutations
of single coding genes [216]. Other pseudogene biotypes
may include polymorphic pseudogenes (loci known to
be coding in some individuals), IG pseudogenes (im-
munoglobulin segments with disabling mutations) and
TR pseudogenes (T-cell receptor gene segments with
disabling mutations) [147].
Hundreds to thousands of pseudogenes have been
identified in different species. In humans, 11,216 pseu-
dogenes have been recently annotated, including ~8,000
processed pseudogenes [61, 147]. The extrapolation esti-
mates suggest that the number of pseudogenes in hu-
man genome may be ~14,000 [147]. This is smaller than
earlier estimates [190, 217]. The processed pseudogenes
are the most abundant type of pseudogenes in human
genome which is connected with the burst of retroposi-
tion activity in ancestral primates [135, 217]. Pseudo-
genes have long been considered as non-functional or
“junk” DNA. But during the last decade, the attitude has
changed substantially. The evidence is accumulating that
many pseudogenes are transcribed and functional in de-
velopment and diseases (reviewed in [105, 148, 154,
173]. Laura Poliseno determines the following types of
pseudogene functions: related to the parental gene and
parental gene independent functions; mediated by the
pseudogene DNA, by pseudogene RNA transcribed in
sense, by pseudogene RNA transcribed in antisense, or
by pseudogene-encoded proteins [154]. Pseudogenes
transcribed as noncoding RNAs may regulate their par-
ental genes as antisense RNAs, short interfering RNAs
(siRNAs) or as microRNA decoys [173]. Pseudogenes
participate in the regulation of variety of biological pro-
cesses including cancer [105, 148, 154]. One of the earli-
est indications of the functional role of pseudogenes was
demonstration that in mouse oocytes pseudogene-
derived small interfering RNAs regulate gene expression
[188, 204]. Besides fully functionally active pseudogenes,
partially active pseudogenes in the process of either los-
ing or gaining function are described [147].
The authors who study pseudogenes come to conclu-
sion that pseudogenes serve as a source of novel func-
tions for the evolving organisms [10, 22, 105]. A special
term – “potogenes – was generated to designate pseudo-
genes as DNA sequences with a potentiality for becom-
ing new genes [10, 22]. This is in accordance with the
major postulate of original hypothesis of evolution by
gene duplication [131], and we may consider pseudo-
genes with novel or evolving functions as evolutionarily
novel or evolving genes.
Transcription of pseudogenes is an important indica-
tion of their functionality. The evidence of pseudogenes
transcription was accumulating during the last years
[10, 219]. The ENCODE and GENCODE projects pro-
vided information about transcription of 876 pseudogenes
including 531 processed and 345 duplicated pseudogenes
[147]. The other group of authors studied RNA-Seq tran-
scriptome data from 248 cancer and 45 benign samples of
13 different tissue types and described the expression of
2,082 distinct pseudogenes [78]. What is important for
our consideration of expression of evolutionarily novel
genes in tumors, they observed 218 pseudogenes
expressed only in cancer samples, of which 178 were
observed in multiple cancers [78].
One of the first demonstrations that pseudogenes are
activated in tumors was description of the new tumor
antigen (NA88-A) generating an HLA class I-restricted
CTL response against melanoma coded for by a proc-
essed pseudogene [126]. At the same time, the expres-
sion of parental gene HPX42B did not lead to similar
CTL response. The transcription of NA88-A pseudogene
was limited with significant expression found only in
some metastatic melanomas [126].
Among other earlier works was detection of ψPTEN
expression in central nervous system high-grade
astrocytic tumors [211]. The ψPTEN expression was
complementary to PTEN mutation because the major-
ity of glioblastomas showed either PTEN mutation or
ψPTEN expression. In the later study [153] the func-
tional relationship between the mRNAs produced by
the PTEN tumor suppressor gene and its pseudogene
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PTENP1 (the other name of ψPTEN) was demon-
strated. PTENP1 was able to regulate cellular levels of
PTEN and exerted a growth suppressive role acting
as a microRNA-decoy [153].
In a comprehensive paper devoted to human proc-
essed pseudogenes Zhaolei Zhang and co-authors [217]
described several pseudogene families with implication
to tumors (see Table 5 in the above mentioned paper).
Other examples of pseudogenes expressed in tumors
but not in normal tissues are presented in Table 2.
As we can see from the data presented in this part of
the paper, the expression of pseudogenes in tumors is
widespread. Thus the evolution of pseudogene towards
functional novel gene may involve its expression in tu-
mors as a part of the whole process (see [91] for more
discussion of the role of gene expression in the origin of
novel genes).
Endoretroviral sequences and other retrotransposons are
expressed in tumors
Transposable elements are classified in two groups,
Class I and Class II. Class I mobile elements use RNA
intermediate and reverse transcriptase activity for trans-
position, while Class II elements use a DNA intermedi-
ate and a ‘cut and paste’ mechanism. Class I elements
include long terminal repeat (LTR) retrotransposons,
also called ‘endogenous retroviruses’ (ERVs), and non-
long terminal repeat (non-LTR) retrotransposons (LINEs
and SINEs) [155]. Human transposable elements com-
prise about 40 % of the human genome: HERVs, 4.64 %;
MaLR, 3.65 %; LINEs, 20.42 %; and SINEs, 13.14 %
[100]. That is why mobile elements were called the
“drivers of genome evolution” [83]. The role of transpo-
sons in gene origin was recently reviewed in [91].
Endogenous retroviruses (ERVs) have been shown to
have originated as the result of repeated germ cell retro-
viral infection of their ancestral hosts [13, 19, 63, 118,
205]. The genes of ERVs were evolutionarily new for
their ancestral hosts. Together with other retrotranspo-
sons, ERVs participated in the origin of genes with the
novel functions to their hosts (reviewed in [91]). There
are 203,000 copies of human ERVs (HERVs) in the hu-
man genome [100]. Different authors define different
numbers of HERV families, from 26 [53] to about 50
[114, 121] or even 350 families [136].
Human endogenous retrovirus sequences are expressed
in tumors [5, 111, 167]. Expression of different HERVs
was described in different human tumors: HERV-K family
– in teratocarcinoma [20], seminomas [167], in breast
cancer [200], in urothelial and renal cell carcinomas [49],
in melanoma, germ cell tumors, gonadoblastoma, ovarian
clear cell carcinoma, ovarian epithelial tumors, prostate
cancer, lymphoma, hematological neoplasms, sarcoma,
bladder and colon cancer [30, 65, 82]; HERV-E – in
prostate carcinoma [201]; HERV-H – in leukemia cell
lines [107] and in cancers of small intestine, bone marrow,
bladder, cervix, stomach, colon and prostate [178].
Recent reviews confirm the upregulation of HERVs
in tumors [80, 113, 127, 158, 161], which is con-
nected with general trend of HERVs demethylation in
tumors [127, 158], and similar data continue to accu-
mulate [26, 181, 208]. ERVs of mice also demonstrate
hypomethylation and transcriptional upregulation in
mice tumors [66, 112, 158].
Endogenous retroviruses may serve as targets for anti-
tumor immunity. For example, HERV-K-MEL, a HERV-K
pseudogene expressed in most melanomas and in many
other types of tumors, encodes the antigenic peptide that
is targeted by CTLs in melanoma patients [30, 169].
HERV-E was found to be selectively expressed in clear
kidney cell cancer but not in normal tissues. This
tumor-specific expression is connected with inactivation
of the von Hippel-Lindau tumor suppressor and hy-
pomethylation. Antigens encoded by HERV-E are im-
munogenic and stimulate cytotoxic T-cells that kill
cancer cells. HERV proteins that act as tumor-
associated antigens have also been detected in other
types of tumors [37].
Especially interesting for my consideration is HERV-K
family because it contains the most recently active mem-
bers that entered the ancestral human genome after the
divergence of humans and chimps and may be consid-
ered as evolutionarily novel for humans [12, 13, 185].
Many HERV-K proviruses are unique to humans [12].
HERV-K continued to replicate in human lineage until
at least 250,000 years ago [114, 117], and might still ex-
pand [113]. HERV-K is also most widely expressed in
different tumors (see above). In HERV-K and in other
younger families such as HERV-H and HERV-W the
most pronounced DNA demethylation was reported
[49, 158]. Not only mRNA, but also HERV-K anti-
bodies are already elevated in the blood at the early
stage of breast cancer [202, 203].
RNA transcripts from various HERV LTRs have been
described in various types of human tumors and cell
lines. For example, elevated HERV-K 5′LTR mRNA was
detected in prostate cancer tissues (reviewed in [207]).
Other primate-specific retrotransposons such as
SVA, LINE-1P, AluY, and MaLR families are also
known for the loss of DNA methylation in tumors.
The younger retroelements are highly methylated in
healthy tissues, while in many tumors these young
elements suffer the most dramatic loss of methyla-
tion [49, 130, 186]. L1 and Alu sequences are si-
lenced in normal human cells and activated in
tumors [14, 155, 171]. Full length L1 RNA in cancer
cell lines and expression of ORF1p in tumors have
been shown (reviewed in [130]). The majority of the
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retrotransposition events seem to be harmless “pas-
senger” mutations [191].
There are in silico data supporting the increased
transcription of retrotransposons in transformed hu-
man cells [41]. Although originally it was thought
that HERVs are transcriptionally silent in most nor-
mal tissues, in silico [57, 84, 166, 178] and PCR and
microarray [6, 50, 140, 174, 179] data suggest that
HERV-derived RNAs are more widely expressed in
normal tissues than originally anticipated. HERV-K is
transcribed during normal human embryogenesis [56].
Syncytin, the envelope gene of human defective endogen-
ous retrovirus HERV-W, is expressed in multinucleated
placental syncytiotrophoblasts and may mediate placental
cytotrophoblast fusion [18, 123, 198].
Genes originated by exon shuffling are expressed in tumors
and may lead to oncogenic transformation
The principle of gene origin by exon shuffling is the fol-
lowing: new genes are created by recombining previously
existing exons that leads to the origin of mosaic genes
and proteins [54, 75, 110, 141–143]. The exon shuffling
is important mode of the origin of new genes: at least
19% of the exons in data base were involved in exon
shuffling [109]. The correlation between exon-intron
organization of the gene and the domain organization of
the corresponding protein is most evident in the case of
young vertebrate genes, e.g. genes coding for proteases
of blood coagulation, fibrinolytic and complement
cascades, etc. That is why the first evidence for exon
shuffling came from studies on proteases of blood co-
agulation and fibrinolysis [143].
The mechanisms of exon shuffling include illegitimate
recombination [192, 193], retroposition [125], segmental
duplication [45] and L1 retrotransposon-mediated 3′
transduction [125].
Modular domain rearrangements can lead to cancer.
The fusion of the self-oligomerizing SAM domain from
the gene TEL to the catalytic domain of the nonreceptor
tyrosine kinase Abl in some human leukemias results in
constitutively clustered chimeric protein, persistent acti-
vation of tyrosine kinase and oncogenic transformation.
Tyrosine kinases other than Abl are also activated in fu-
sion proteins by oligomerization of SAM domain of TEL
[106]. Activation of Abl tyrosine kinase seen in patients
with chronic myelogenous leukemia is caused by




HERV-K-MEL Expressed in melanomas,
sarcomas, lymphomas, bladder
and breast cancers, but not in
normal tissues
[30, 169]
CYP4Z2P A pseudogene of mammary-
restricted cytochrome CYP4Z1,
shows 4.8 times higher
transcription level in breast
cancer tissue than in normal
mammary gland with almost
no transcription in other tissues
[157]
ΨCx43 Connexin43 (CX43) pseudogene
was shown to be expressed in
mammary cancer cell lines and
to inhibit growth. ΨCx43 acts as
a posttranscriptional regulator of
CX43 in breast cancer cells
[17, 79]
rac1 The rac1 processed pseudogene
overexpression was detected in
the human brain tumors as





Oct4 and Nanog, embryonic stem
cell-specific genes coding for
transcription factors, have multiple
retropseudogenes, expressed in








A processed pseudogene POU5F1P1
(POU5F1 is another name of Oct4) is
overexpressed in prostatic carcinoma,
and OCT4-pg1, OCT4-pg3 and OCT4-pg4
were found to be expressed in glioma
and breast carcinoma. POU5F1B (also
known as Oct4-pg1 and POU5F1P1) is
amplified and promotes aggressive
phenotype to gastric cancer.
[62, 81, 206,
218]
CRIPTO3 A presumed pseudogene expressed
in many cancer samples
[183]
BRAF Expression of BRAF pseudogene was
described in thyroid tumors.
[220]
CSNK2A1P Protein kinase CKα intronless gene
CSNK2A1P, a presumed CK2α
pseudogene, plays the oncogenic
role in lung cancer. It is amplified and
over-expressed in non-small cell lung
cancer and leukemia cell lines and in
lung cancer tissues.
[67]
MYLKP1 A transcribed pseudogene MYLKP1 is
strongly expressed in cancer cells and
its parental gene MYLK is highly
expressed in non-neoplastic cells.
[60]
MO1P3 SUMO1P3 pseudogene-expressed
lncRNA is up-regulated in gastric
cancer tissues and may be a





The overexpression of HMGA1
pseudogenes HMGA1P6 and HMGA1P7
is induced in human pituitary tumors
and anaplastic thyroid carcinomas.
[47, 48]
Table 2 Pseudogenes expressed in tumors (Continued)
CGB1
CGB2
CGB1 and CGB2 are transcribed in
ovarian cancer tissues and in epithelial
cancer cell lines
[25, 98, 187]
ψPPM1K Transcribed pseudogene ψPPM1K exerts
tumor-suppressor activity in hepatocellular
carcinoma by generation of siRNA
[31]
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translocation of the tip of chromosome 9 encoding Abl
to chromosome 22 encoding BCR and formation of fu-
sion protein. Oligomerization of coiled-coil domains
from BCR leads to constitutive activation of Abl [106].
The Tre2(USP6) oncogene is a hominoid-specific
gene. It originated by the fusion of two genes, USP32
(NY-REN-60) and TBC1D3. USP32 is an ancient gene
and highly conserved. TBC1D3 is young and originated by
recent segmental duplication in primates. Tre2 is young
for humans as far as it originated 21–33 million years ago
after TBC1D3 segmental duplication in primates [144].
Atypical splicing in combination with retrotransposi-
tion may also lead to exon shuffling. Moreover atypical
splicing of existing genes may be the most prevalent
mechanism of novel protein creation. Atypical splicing
includes alternative splicing within the single-gene
transcripts and intergenic splicing of transcripts from
tandemly located genes. Transcription-induced chi-
meras may evolve into gene fusions, and alternative
splicing may evolve to gene fission (reviewed in [8]).
For instance, the chimeric PIPSL gene was formed by
L1-mediated retrotransposition of a readthrough, inter-
genically spliced transcript in hominoids [9]. This
phenomenon was called transcription-mediated gene
fusion. Many examples of intergenic splicing have been
described in the human genome. The authors suggest
that it is a novel mechanism of gene origin, where
transcription-induced chimerism followed by retroposi-
tion may result in new gene [2]. At least 4 %–5 % of
the tandem gene pairs in the human genome can be
transcribed into a single RNA coding for chimeric pro-
tein [139].
Alternative splicing often participates in exonization
process. When the new exon is alternatively spliced and
expressed at low levels, splice variants with and without
new exon are represented, and the pre-existing function
is not destroyed. This opens the way to the origin of
new gene with a new function and/or new functional
module due to novel exon [54, 128, 177, 199]. The com-
parison of human, mouse and rat genomes indicates that
alternative splicing is associated with an increased fre-
quency of exon creation and/or loss [124].
Transposed element exonization may be a source of
new constitutively spliced exons. Alu-containing exons
are alternatively spliced. Comparative analysis of trans-
posed element insertion within human and mouse ge-
nomes reveals Alu’s unique role in shaping the human
transcriptome [172, 176].
The alternative splicing is widespread in cancer. The
splice changes in cancer are global. Up to half of all al-
ternative splicing events may be changed in tumors.
Some splice isoforms are upregulated in all studied can-
cers, the others are characteristic to certain types of tu-
mors. Affected proteins include transcription factors,
cell signal transducers, transmembrane proteins, se-
creted extracellular proteins, proteins involved in metab-
olism, angiogenesis, apoptosis, cell motility and invasion,
oncoproteins and tumor suppressor proteins. Genes with
alternative transcripts associated with various cancers in-
clude CD44, p53, p73, PTEN, APC, BCL-X, VEGF4,
mdm2, BRCA1, TACC1, TERT, KLF6, SURVIVIN, ASIP,
NF1, Caspase 8, CDH17, Ron, BARD1, AR, FGFR2,
RUNX1, HOXA9, WT1, BIM, TF, HERV-K env (np9),
HNRPK and many others. Many of these genes have
multiple splicing patterns, e.g. mdm2 gene locus pro-
duces over 72 mdm2 variants. Alternative splicing in
cancer-related genes may have impact on all major aspects
of tumor cell biology. All hallmarks of cancer have alter-
natively spliced regulators. There are also many cancer-
associated splice variants with unknown functions [7, 35,
42, 52, 59, 85, 101, 102, 133, 156, 160, 182, 195, 196].
Atypical splicing events do not alter the number of genes
in DNA, but produce altered proteins which influence all
aspects of tumor biology. In evolutionary perspective, atyp-
ical splicing combined with retrotransposition may lead to
the origin of novel genes. The promising direction of re-
search would be to study what proportion of spicing events
involved in cancer have already generated (through retro-
position) novel genes in the germ plasm.
Genes originated de novo are specifically expressed in
tumors
“Senseless” DNA sequences may acquire new functions
in the organism and become new genes. New func-
tions may be connected not only with protein-coding
genes, but also with various functional non-coding
RNAs. This mechanism of novel genes origin is called
de novo origin.
New promoter elements such as GC-islands, TATA-
boxes, LINE1 promoters or retroviral LTRs may arise as
a result of mutational process, gene rearrangements, ret-
rotransposition or viral infection. Such events can lead
to expression of “senseless” DNA sequences that subse-
quently may accumulate mutations that alter their
protein-coding capacity. The senseless DNA sequences
acquire new functions. Noncoding RNAs may eventually
acquire ORFs and become protein-coding mRNAs.
These could be mechanisms of de novo gene origin. Exo-
nization by alternative splicing may be the mechanism
of de novo exon origin (see discussion above in Genes
originated by exon shuffling are expressed in tumors and
may lead to oncogenic transformation).
Three novel human protein-coding genes have been
shown to originate from noncoding DNA since the
divergence with chimp. These genes have no protein-
coding homologs in any other genome. Few human-
specific mutations altered protein-coding capacity by
destroying “disablers” in the ancestral sequences. The
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existence of protein-coding genes is supported by ex-
pression and proteomic data [86]. One of those genes
– CLLU1 – has been shown earlier to be specifically
expressed in chronic lymphocytic leukemia (CLL)
[23]. The CLL expression specificity of CLLU1 was
later confirmed in several studies [24, 74, 134, 159].
It was also shown that CLLU1 is expressed in other
tumors (tumors of lung, stomach, prostate and
spleen), but in no normal tissue [[97], in press]. We
may conclude that CLLU1 belongs to TSEEN genes.
PBOV1, a gene of the recent de novo origin specific to
humans, has highly tumor-specific expression profile
[165] (see discussion above in PBOV1, de novo origi-
nated human gene with tumor-specific expression).
PBOV1 expression levels positively correlate with
relapse-free survival in breast cancer patients and with
overall longitude of survival in glioma patients [165]. On
the contrary, CLLU1 is highly expressed in poor-
prognostic patients [23, 24, 74, 134, 159].
Positive selection of human tumor-related genes in primate
lineage
Positive Darwinian selection participates in the evolution
of the novel genes. Comparison of the rate of amino acid
replacement substitution with the rate of synonymous
substitution, population genetic analyses of polymor-
phisms and the findings of convergent evolution support
the adaptive evolution of the novel genes. There are many
examples of rapidly evolving novel genes and gene families
supported by positive selection. In humans, strong positive
selection and accelerated evolution was documented for
lactase gene and for many other genes with different mo-
lecular functions, e.g. transcription factors, genes in-
volved in nuclear transport, DNA metabolism/cell
cycle, protein metabolism, pigmentation pathways,
dystrophin protein complex, heat shock proteins; vari-
ous types of genes related to sensory perception, im-
mune response, reproduction, morphology, host-
pathogen interactions, and neuronal functions. Exam-
ples of positively selected gene families are also nu-
merous, including those in African great apes and
hominids. Several gene families have expanded or
contracted rapidly in primates, including brain-related
families in humans. Many of such families show evi-
dence for positive selection. The proportion of posi-
tively selected genes is significantly higher in younger
genes in humans, i.e. positive selection may play a
role in faster evolution of younger genes. Many exam-
ples of rapid evolution and positive selection of new
genes described in the literature points out that this
phenomenon is widespread. It supports involvement
of novel genes and gene families in adaptation and
speciation and in evolution and enhancement of new
functions (reviewed in [91]).
For our consideration, it is important that positive se-
lection in primate lineage was described for many hu-
man tumor-related genes [39, 40, 43, 129, 145, 180].
SPANX, GAGE, PRAME and CTAGE families of
cancer/testis antigen genes, with unknown functions
yet, undergo positive selection in primate evolution
[43, 55, 87, 108, 214]. Comparison of human/chimp
orthologues of CT-X genes has shown that they di-
verge faster and undergo stronger positive selection
than those on the autosomes [180].
Adaptive evolution of the tumor suppressor BRCA1 in
humans and chimps was demonstrated [68]. Most of the
internal BRCA1 sequence is variable between primates
and evolved under positive selection [145].
Angiogenin (ANG) is the tumor-growth promoter due
to its ability to stimulate the formation of new blood
vessels. Its expression is elevated in variety of tumors.
The study among several primate species showed that
ANG gene has a significantly higher rate of nucleotide
substitution at nonsynonymous site than at synonymous
sites, an indication of positive selection [212].
Comparison of 7645 chimp gene sequences with their
human and mouse orthologs showed accelerated evolu-
tion in functions related to oncogenesis [39]. A search
for positively selected genes in the genomes of humans
and chimps showed the evidence for positive selection in
many genes involved in tumor suppression, apoptosis
and cell cycle control [129].
More examples of positively selected tumor-related
genes are reviewed in [40].
Positive selection of many human tumor-related genes
in the evolution of primates confirms the prediction of
evolution by tumor neofunctionalization hypothesis con-
cerning expression of evolutionarily new genes in tu-
mors and selection for their new organismal functions. If
an evolutionarily new gene is expressed in tumors, or a
sequence that is expressed in tumors acquires a function
beneficial to the organism and becomes an evolutionarily
new gene, selection of organisms for the enhancement
of the new function should take place, as predicted by
the hypothesis. This is exactly what was found in papers
discussed above: the positive selection of genes and pro-
teins in different primate groups, not the somatic evolu-
tion of tumor cells. More discussion of positive selection
in relation to the possible evolutionary role of tumors
may be found in [91].
The paradox of the positive selection of many tumor-
associated genes is difficult to explain otherwise than by
the postulation that tumors play a positive evolutionary
role. The other attempt to explain positive selection of
tumor-related genes is based on the concept of genomic
conflict and antagonistic coevolution [40, 129].
Some evolutionarily novel genes are cellular onco-
genes. The Tre2(USP6) oncogene is a hominoid-specific
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gene [144] (see discussion above in part 2.3). Evolution-
arily novel genes CT45A1, TBC1D3 and NCYM may act
like oncogenes (reviewed in [215]). Y. Zhang and M.
Long suggest that these genes may also assume other
biological functions, and attract the selection, pleiotropy
and compensation hypothesis of M. Pavlicev and G.P.
Wagner [146] to explain the paradox related to their
oncogene role.
Conclusion
The phenomenon of tumor specifically expressed,
evolutionarily novel genes (TSEEN genes)
This review discusses the data obtained in my lab and
the data described in the literature. My group looked for
genes with dual specificity, i.e. evolutionarily novel and
tumor specifically expressed. We studied single genes,
the complex class of CT genes with many gene families,
and two newly described gene classes obtained by global
subtraction of normal cDNA sequences from tumor
cDNA sequences. Using different approaches, we have
been able to describe many genes with tumor specific or
tumor predominant expression which are also evolution-
arily novel or young.
We have also described tumor-specifically expressed,
evolutionarily new sequences which look like proto-
genes, i.e. gene precursors which have not yet acquired
functions and evolve neutrally. Expression of proto-
genes, novel and young genes in tumors may represent
different stages of the origin of a new genes and novel
organismal functions (which are not related to tumor
progression) in multicellular organisms.
The analysis of published information about evolution-
arily novel genes and/or sequences originated through
different molecular mechanisms (by gene duplication,
from endogenous viruses and retrotransposons, by exon
shuffling or de novo) reveals that evolutionarily novel
genes/sequences tend to be expressed predominantly in
tumors, independent of the mechanism of origin. Some-
times the expression of evolutionarily novel genes in tu-
mors is highly specific. Moreover, positive selection of
many human tumor-related genes in primate lineage
suggests their involvement in the origin of new functions
beneficial to organisms.
I suggested considering the expression of evolutionar-
ily young or novel genes in tumors as a new biological
phenomenon, a phenomenon of TSEEN (tumor specific-
ally expressed, evolutionarily novel) genes [91]. This
phenomenon is similar to phenomenon of carcinoem-
bryonic antigens in that it represents a phenomenon of
dual specificity, i.e. evolutionary and tumor specificities.
Some TSEEN genes are oncogenes, the others acquired
functions beneficial to organism, but many TSEEN genes
have no known functions. The lack of know functions is
usually associated with the youngest TSEEN genes. We
may infer that they are in the process of acquisition of
function in the organism as suggested by positive selec-
tion of many of them in primate lineage.
TSEEN genes may thus represent a new interesting
link between different but connected processes of gene
origin, genome evolution, tumorigenesis and progressive
evolution.
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